For the first time ever, a new European Patient Charter for patients who suffer from idiopathic pulmonary fibrosis (IPF) was developed by a group of advocates and presented to the European Parliament on September 30, during IPF World Week 2014. Biotechnology company InterMune, which is dedicated to research, development,…
The U.S. Food and Drug Administration (FDA) organized a workshop on pulmonary fibrosis, which took place on September 26th, in collaboration with the Coalition for Pulmonary Fibrosis (CPF), with the purpose of advocating for the disease throughout the country. Four of the eight panelists at the…
Founded in 2000, the Pulmonary Fibrosis Foundation (PFF) is a nonprofit organization dedicated to supporting research on the treatment of pulmonary fibrosis (PF) and finding a cure for the disease, as well as assisting patients and their families. The organization engages with local and regional PF communities all over the…
The Pulmonary Fibrosis Foundation (PFF) recently submitted research data about more than 1,100 patients who suffer from pulmonary fibrosis (PF) to the U.S. Food and Drug Administration (FDA), in order to participate in the Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis. The meeting will take place on September…
Half of it has already passed, but the 2014 Pulmonary Fibrosis Awareness Month in September continues forward, full of activities. Having been established by the Coalition for Pulmonary Fibrosis (CPF), this is the 12th year that the organization is using the month to raise awareness for…
Pharmaceutical company Boehringer Ingelheim Pharmaceuticals, Inc. is sponsoring the documentary Every Breath Counts: Idiopathic Pulmonary Fibrosis, which will air on the Discovery Channel on September 13th and 27th at 8:00 am ET/PT, and can also be viewed at www.everybreathcountsfilm.com. The documentary was created in collaboration with the Pulmonary…
Cases of idiopathic pulmonary fibrosis (IPF) may be caused by exposure to asbestos, as suggested by a recent study conducted at Imperial College London in the United Kingdom, and presented at the European Respiratory Society’s conference. The new mortality data about IPF, asbestosis, and mesothelioma may offer new information for how to…
The clinical stage specialty pharmaceutical company Pacific Therapeutics announced that is looking for a commercialization partner for the sale of PTL-202, as a result of positive results of recent pre-clinical studies and an initial phase I clinical trial of its lead drug candidate for pulmonary fibrosis. PTL-202 is a combination of…
Plant-based biotechnology company iBio, specializing in developing and manufacturing biological products, was recently granted notices of intention for two European patent applications claiming novel protein expression technologies. iBio is also currently developing a proprietary product for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, among other fibrotic diseases using…
An advocacy group associated with the Coalition for Pulmonary Fibrosis (CPF) called The Daughters of PF engaged in a national awareness campaign to raise awareness of pulmonary fibrosis, beginning in the Atlanta area and taking place during National Pulmonary Fibrosis Month, which starts in September. The first event organized was last Sunday, when the members of group dressed…
Get regular updates to your inbox.
